SP
Therapeutic Areas
Humacyte Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Symvess™ (ATEV) | Vascular Trauma Repair | Approved |
| ATEV (HUM-001) | Arteriovenous (AV) Access for Hemodialysis | Phase 3 |
| ATEV | Peripheral Arterial Disease (PAD) | Phase 2/3 |
| BioVascular Pancreas™ | Type 1 Diabetes | Preclinical |
| Lung | Respiratory Disease | Preclinical |
| Urinary Conduit | Bladder Cancer/Cystectomy | Preclinical |
| Tracheal Replacement | Tracheal Damage/Disease | Preclinical |
| Esophageal Replacement | Esophageal Disease | Preclinical |
Leadership Team at Humacyte
LE
Laura E. Niklason, M.D., Ph.D.
Founder, President, Chief Executive Officer
DS
Dale Sander
Chief Corporate Development Officer, Chief Financial Officer & Treasurer
SO
Sabrina Osborne, GPHR, SPHR, CPC
Chief People Officer
LM
Lisa Molyneux
Executive Vice President, Enterprise Planning & Analysis
HC
Heather Connelly, Ph.D.
Executive Vice President, Regulatory Affairs & Quality